Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174566 | 1.00 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL4391338 | 1.00 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL4392273 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL4392278 | 0.97 | TSHR (0.54) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL2532323 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL9586011 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL5184469 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7339345 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7337864 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL874675 | 0.97 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111684633-B | Binder for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | 株式会社LG新能源 | 2023-10-31 | — | — | CN | claimed |
| US-20210083292-A1 | BINDER FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY INCLUDING SAME | LG CHEM, LTD. (KR) | 2021-03-18 | — | — | US | claimed |
| CN-111684633-A | Binder for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | 株式会社LG化学 | 2020-09-18 | — | — | CN | claimed |
| EP-3709408-A1 | BINDER FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY INCLUDING SAME | LG CHEM, LTD. (KR) | 2020-09-16 | — | — | EP | claimed |
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-0666847-B1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMA (CA) | 1998-06-17 | — | — | EP | claimed |
| US-5496957-A | 5-HYDOXYTRYPTAMINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-05 | — | — | US | claimed |
| EP-0666847-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | Allelix Biopharmaceuticals Inc. (CA) | 1995-08-16 | — | — | EP | claimed |
| WO-1995006638-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-03-09 | — | — | WO | claimed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20240132675-A1 | POLYMER HAVING METAL-OXYGEN-METAL BOND AS PRIMARY CHAIN, COMPOSITION THEREOF, SOLID MATERIAL AND PRODUCTION METHOD THEREOF, AND ELECTRONIC COMPONENT AND FIBER | TORAY INDUSTRIES, INC. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11932715-B2 | Hardmask composition and method of forming patterns | SAMSUNG SDI CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| EP-0054946-A1 | Basic substituted pyridazines, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1982-06-30 | — | — | EP | disclosed |
| EP-0051261-A1 | Process for the production of discharge-resist prints on textile materials | CASSELLA Aktiengesellschaft (DE) | 1982-05-12 | — | — | EP | disclosed |
| US-4216314-A | CARDIOSELECTIVE B-ADRENOLYTIC AGENTS, ANTIARRHYTHMIC AGENTS AND HYPOTENSIVE AGENTS | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DE) | 1980-08-05 | — | — | US | disclosed |
| US-3992405-A | ESPECIALLY FOR DYEING POLYACRYLIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3988142-A | Increasing carbohydrate deposition in plants with N-phosphono-methylglycine and derivatives thereof | MONSANTO COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814393-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | TSHR 2653/4885CYP3A4 302/4885MEN1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.